The molecular understanding of brain tumors has undergone a profound transformation in recent years. Advances in genomics, ...

Oversubscribed GBP2.5M seed round led by Ahren Innovation Capital -- Strategic collaboration with o2h to progress drug discovery programme CAMBRIDGE, England--(BUSINESS WIRE)--January 12, 2026-- ...

A significant portion of disease-relevant proteins remain “undruggable” by traditional therapeutic approaches, representing a major hurdle in drug discovery. Targeted protein degradation (TPD) is ...

Gastrointestinal (GI) cancers, encompassing esophageal, gastric, small bowel, and colorectal carcinomas, represent a significant global health burden due to their high incidence and mortality rates.

The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic modelsMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer ...

Researchers at the University of Michigan have identified a novel way to counter drug resistance in KRAS-mutant non-small ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

SAN JOSE, Calif., Oct. 23, 2025 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today that three ...

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...

Dynamic, reversible modifications of DNA and RNA regulate how genes are expressed and transcribed, which can influence cellular processes, disease development, and overall organismal health. Small ...